| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. | SVP, Regulatory Affairs | Stock Option (right to buy) | 9,000 | 02 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| DRMA | Dermata Therapeutics, Inc. | 02 Jan 2026 | 1 | $0 | 4 | SVP, Regulatory Affairs | 06 Jan 2026, 20:00 |
| DRMA | Dermata Therapeutics, Inc. | 13 Jan 2025 | 1 | $0 | 4 | SVP, Regulatory Affairs | 14 Jan 2025, 18:56 |
| DRMA | Dermata Therapeutics, Inc. | 04 Jan 2024 | 1 | $0 | 4 | SVP, Regulatory Affairs | 05 Jan 2024, 21:00 |
| DRMA | Dermata Therapeutics, Inc. | 03 Jan 2023 | 1 | $0 | 4 | SVP, Regulatory Affairs | 05 Jan 2023, 15:06 |
| DRMA | Dermata Therapeutics, Inc. | 03 Jan 2022 | 1 | $0 | 4 | Senior Vice President | 05 Jan 2022, 17:59 |
| DRMA | Dermata Therapeutics, Inc. | 17 Aug 2021 | 12 | $0 | 4 | Senior Vice President | 17 Aug 2021, 12:51 |
| DRMA | Dermata Therapeutics, Inc. | 12 Aug 2021 | 0 | $0 | 3 | Senior VP | 12 Aug 2021, 19:43 |